Article: OTC Claritin prompts coverage decisions.

When Schering-Plough's non-sedating antihistamine (NSA) Claritin went over the counter last December, plan sponsors confronted a big question: What coverage would they now provide for other prescription-only NSAs like Allegra, Zyrtec, and Clarinex?

Sponsors naturally began to weigh economic incentives to steer consumers toward OTC Claritin, which at a ballpark cost of $30 for a month's supply is much cheaper than prescription-based alternatives - and less than half of Claritin's cost as a prescription drug. While it's too soon to puzzle out the choices employers are making, health industry representatives caution that there are pros and cons to every benefit ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!